Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.
“Prokarium is designing the perfect bacteria to be the next cancer immunotherapy, and we believe leveraging Salmonella’s unique biology will allow us to combine a powerful innate approach with a tailored adaptive response,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.”
This new multi-year agreement builds on work between Prokarium and London Biofoundry that was initiated in 2020 and will further expand Prokarium’s operations. The team from Imperial’s and SynbiCITE’s London Biofoundry specializes in the design, engineering and functional characterisation of synthetic DNA and organisms.
“Prokarium has uniquely positioned their Salmonella platform as an innovative immunotherapy approach for the treatment of solid tumors, and we are excited to support their efforts in pioneering the cancer treatment paradigm shift from synthetic chemistry to synthetic biology,” said Marko Storch, PhD, Head of Synthetic Biology and Automation. “At the London Biofoundry, we developed a cutting-edge SynBio stack and the expertise to collaborate with researchers and biotechs to advance their R&D. We are thrilled to leverage our leading research capabilities to support the development of Prokarium’s new class of medicines in oncology.”
About the London Biofoundry
The London Biofoundry provides a suite of state-of-the-art robotic equipment and expertise supporting automated end-to-end design, construction, and validation of large gene constructs and biological systems. For more information visit www.londonbiofoundry.org
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. For more information visit http://www.imperial.ac.uk/
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005069/en/
Contact information
Contacts
For Prokarium
Kristen Albright
Chief Executive Officer
kristen.albright@prokarium.com
www.prokarium.com
For media
MacDougall Advisors
Matthew Corcoran
+1 781-235-3060
prokarium@macdougall.bio
www.macdougall.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Euromonitor International unveils Global Consumer Trends for 20265.11.2025 15:00:00 EET | Press release
Data analytics company Euromonitor International has today revealed its top Global Consumer Trends for 2026, with the annual report identifying four global trends that highlight crucial shifts in consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105486775/en/ Euromonitor International Global Consumer Trends 2026 In a reality shaped by cost of living, authenticity and wellbeing expectations, these trends are at the core of consumer behaviour worldwide. Alison Angus, head of innovation at Euromonitor International, said: “The future of consumer behaviour is characterised by a desire for comfort, self-expression and cutting-edge wellness solutions, driven by the need for authenticity and simplicity in an increasingly complex world.” Euromonitor’s top Global Consumer Trends in 2026 are: Comfort Zone: Consumers are seeking comfort and simplicity amid global volatility, with 58% experiencing moderate to extreme
Merz Aesthetics ® Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only Ultrasound Solution With Integrated Real-Time Visualization5.11.2025 15:00:00 EET | Press release
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the upcoming availability of UltherapyPRIMEto improve the appearance of skin laxity on the anterior arms and posterior arms, and abdomen. Ultherapy PRIME is the only solution with integrated real-time visualization to treat the upper face, lower face, neck, décolleté, and now the body*.1 The new indications will launch in the United States before expanding to markets worldwide, with commercial rollout in EMEA planned for early 2026.** We are excited to share updates with our customers soon and look forward to supporting practices and patients with these innovative solutions. “This indication expansion is proof of our incredible momentum, following last year’s successful Ultherapy PRIME launch,” said Bob Rhatigan, CEO, Merz Aesthetics. “By extending our reach from face*** to body*, we’re unlocking new treatment possibilities, meeting rising patient demand, and reinforcing our leadership in non-in
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 14:00:00 EET | Press release
Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even greater value to our clients,” said Manuel Mateos, CEO of CMC Medical Devices. “Our sha
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 14:00:00 EET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 14:00:00 EET | Press release
Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Founder of Armis: “This round marks another defining moment in our journey to build a category-defining cybersecurity company. Our growth proves that organizations are embracing a unified, exposu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom